Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Novo Nordisk is broadening its Bengaluru operations by increasing senior leadership, doubling global process leaders in India, and boosting headcount by 16% next year. The company is also ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Ozempic, Wegovy, and Eli Lilly And Co's (NYSE:LLY) Mounjaro and Zepbound have fueled an illicit market of counterfeit and ...

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...